8 completed, 1 terminated. 4 Phase 3, 3 Phase 1, 3 Phase 2.
By phase and status
Follow OGX-011: new trials by email Literature Review of OGX-011 trials Research Report on OGX-011
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization
Custirsen, Placebo, Moxifloxacin - Cardiac Conduction and Repolarization | Phase 1 | Completed | Achieve Life Sciences | 155 | 2013-05-01 | 2016-10-10 |
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
Custirsen, Docetaxel - Non-Small Cell Lung Cancer | Phase 3 | Completed | Achieve Life Sciences | 664 | 2012-10-24 | 2026-04-15 |
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
cabazitaxel, prednisone, custirsen sodium - Prostate Cancer | Phase 3 | Completed | Achieve Life Sciences | 630 | 2012-08-01 | 2016-10-12 |
A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen
Custirsen, paclitaxel and carboplatin - Cancer | Phase 1 | Completed | Achieve Life Sciences | 36 | 2012-04-01 | 2016-10-10 |
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Custirsen, Docetaxel, Prednisone - Prostate Cancer | Phase 3 | Completed | Achieve Life Sciences | 1022 | 2010-11-01 | 2016-10-14 |
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
custirsen sodium, isotonic, 0.9% sodium chloride, docetaxel - Castrate-Resistant Prostate Cancer, Hormone Refractory Prostate Cancer | Phase 3 | Terminated | Achieve Life Sciences | 14 | 2010-03-01 | 2016-10-12 |
Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC
custirsen (OGX-011)/mitoxantrone, custirsen (OGX-011)/docetaxel - Prostate Cancer | Phase 2 | Completed | Achieve Life Sciences | 70 | 2006-07-01 | 2012-10-05 |
Study of OGX-011 Given Prior to Radical Prostatectomy in Patients With Localized Prostate Cancer
OGX-011 - Prostate Cancer | Phase 2 | Completed | University of British Columbia | 20 | 2005-06-01 | 2017-03-03 |
A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
custirsen sodium - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Achieve Life Sciences | 85 | 2004-11-01 | 2012-02-06 |
Conditions studied
Prostatic Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (2) · Neoplasms (2) · Lung Neoplasms (1) · Neoplasm Metastasis (1)
Sponsors
Achieve Life Sciences (8) · University of British Columbia (1)
Countries
United States (7) · Canada (6) · France (3) · Hungary (3) · Spain (3) · United Kingdom (3) · Australia (2) · Germany (2) · Israel (2) · Italy (2) · Russia (2) · South Korea (2) · Belgium (1) · Czechia (1) · Netherlands (1)
Top investigators
Celestia Higano, MD (1) · Dr. Kim Chi (1) · Eric Winquist, MD, MSc (1) · Fred Saad, MD, FRCS (1) · Janessa Laskin, M.D. (1) · Joachim Von Pawel, MD (1) · Johann de Bono, Professor (1) · Karim Fazazi, MD (1) · Karim Fizazi, M.D., Ph.D. (1) · Kim Chi, MD (1) · Sebastien Hotte, MD (1) · Sebastien J Hotte, M.D. (1) · Thomasz Beer, MD (1) · Tomasz M Beer, M.D. (1)
Results publications
PMID 21788353, PMID 22198426, PMID 24156019, PMID 24722180, PMID 28283282, PMID 29033099